Evox’s mission is to build a platform technology company spearheading the translation of exosome therapeutics for the treatment of serious, life-threatening diseases with limited options for patients and their families.
Exosomes are increasingly seen as foundational transporters in the human body’s own communication machinery and Evox’s technology development is unwaveringly focused on exploiting this natural mechanism for creating a novel form of biotherapeutics. Exosomes have been shown to be able to transport various types of biomacromolecules – for instance protein and RNA therapeutics – but also various types of small molecule drugs. Evox combines the highly versatile delivery capabilities of exosomes with targeting technology, sophisticated biomolecular engineering approaches, and large-scale production methodology, to enable the development of natural delivery nanoparticles for the treatment of severe diseases with validated therapeutic targets.
With its roots firmly grounded in two world-renowned academic institutions – the University of Oxford and the Karolinska Institute – Evox is driven by a dedication to scientific excellence and to pushing the scientific frontier together with an ecosystem of academic partners and collaborators worldwide (LINK TO EVOX’S ECOSYSTEM)
A key component of Evox’s technology platform relates to engineering of exosome proteins for optimized loading of drug cargos and targeting moieties into and onto exosomes.
Evox’s proprietary protein engineering technology enables loading of protein therapeutics and targeting moieties onto the surfaces of exosomes, which enables tissue targeting and display of therapeutic proteins. Additionally, Evox protein engineering strategies comprise methods for loading the inside of exosomes and extracellular vesicles with various types of drug cargo, notably therapeutic proteins and nucleic acids. This modulation of the protein composition of exosomes is key to developing potent therapeutics harnessing both the native effects of exosomes and the specificity and affinity of conventional biologics, such as monoclonal antibodies and siRNAs.
Nucleic acid-based therapeutics constitute a core therapeutic modality for Evox’s development programs and we have sophisticated capabilities for loading of primarily RNAs into exosomes.
RNA loading is done via either proprietary exogenous or endogenous loading methods, which enables Evox to work across both natural and non-natural oligonucleotides. Solving the non-hepatic delivery challenge of nucleic acid-based drugs – such as siRNAs, antisense or even gene editing modalities – is a core mission for Evox and tissue-targeted exosomes represent a very promising technology to achieve this.
Targeting & Biology
Targeted delivery of nanoparticles is an area that has been intensely investigated for decades. Methods for delivering a drug at a high concentration to a specific organ or tissue in the human body are meant to enhance efficacy while reducing unwanted side effects and toxicity. Targeted drug delivery has a role to play in the delivery of many if not all drugs, but targeted delivery systems are absolutely critical for delivery of nucleic acid-based agents such as siRNA and CRISPR-Cas technology.
Unlike many other nanoparticle-based delivery systems, exosomes are easily modified to contain targeting entities to enable tissue- and organ-specific delivery. Evox has created substantial proprietary technology to modify exosomes using various targeting strategies to facilitate targeted drug delivery to organs of interest, not least to the brain and the central nervous system. Our R&D teams are in constant pursuit of novel targeting strategies for enhancing exosome-mediated delivery to tissues of interest and combining this with the inherent biology of exosomes to further drive optimal in vivo behavior.
Although exosomes are a novel form of biotherapeutics their production and purification is highly similar to conventional monoclonal antibody production, both in terms of upstream and downstream processes. Evox is therefore investing significant resources to capitalize on advances made within protein production and our exosome manufacturing lines rely on some of the latest technologies for cell line development, cell culturing, exosome harvesting, and exosome purification. We also focus intensely on optimizing the pharmaceutical compositions, to ensure that we harness the biology and the potency of exosomes as efficiently as possible.
Pipeline and programs
Evox’s development programs are leveraging the unique inherent abilities of exosomes, namely to modulate the immune system and to target hard-to-reach tissues and organs. Accordingly, Evox’s development pipeline is initially focused on inflammatory and immunologically driven diseases, neuroscience, and on various rare diseases with significant unmet medical need.
Utilizing its holistic technology platform, Evox is working across therapeutic modalities its lead candidates are based on delivery of both protein therapeutics and nucleic acid-based drugs.
Intellectual property estate
Evox has created a comprehensive intellectual property portfolio encompassing key aspects of EV-based drug delivery technology. Coupled with tailored targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across several disease areas, using a wide array of therapeutic modalities.
- Key aspects of Evox’s intellectual property portfolio includes:
- Exosomes for delivery of nucleic acid-based agents
- Exosomes for delivery of protein therapeutics, including antibodies, antibody fragments, and receptors
- Targeting of exosomes to tissues and organs of interest
- Exosomes for small molecule delivery